Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

Virology(2020)10.1016/j.virol.2020.05.002Source: DataRank Database

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells is a research paper published in Virology (2020). On theSindex it has a DataRank of 0. It has been cited 162 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access162 citations

Download PDF

Cite:

Linked data & code

refseq doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.14)OA: bronzeTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Shannon Stone ORCID,Janhavi P. Natekar ORCID,Pratima Kumari ORCID,Komal Arora ORCID,Mukesh Kumar ORCID

Live enrichment

PubMed:32442105 PMC:PMC7236683 OpenAlex:https://openalex.org/W3024856896

NINDS NIH HHS

Grant: R21 NS099838

NIH HHS

Grant: R21 OD024896

NIH Office of the Director

National Institute of Neurological Disorders and Stroke

FWCI

3.14

Citation Percentile

1.0%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttps://www.sciencedirect.com/science/article/pii/S0042682220300817/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0042682220300817/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0042682220300817?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0042682220300817?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.virol.2020.05.002

Fields of Study

SARS-CoV-2 and COVID-19 ResearchSirtuins and Resveratrol in MedicineMosquito-borne diseases and controlAntiviral AgentsAuranofinBetacoronavirusCOVID-19Cell LineCoronavirus InfectionsCytokinesDrug Evaluation, PreclinicalGoldHumansInflammationPandemicsPneumonia, ViralSARS-CoV-2Virus Replication

MeSH Terms

BetacoronavirusCOVID-19SARS-CoV-2Antiviral AgentsAuranofinCell LineDrug Evaluation, PreclinicalGoldHumansInflammationPneumonia, ViralVirus ReplicationCytokinesCoronavirus InfectionsPandemics

Keywords

AuranofinDrugBiologyInflammationPharmacologyViral replicationDrug developmentCoronavirusDrug repositioningAntiviral drugVirologyImmunologyCoronavirus disease 2019 (COVID-19)DiseaseMedicineVirusInternal medicineInfectious disease (medical specialty)Anti-inflammatoryAntiviralCovid-19Sars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)